Literature DB >> 35800421

Incidental Synchronous 99mTc-HYNIC-TOC Avid Lesion of the Neck in a Patient with Metastatic Melanoma: A Metastatic Lymph Node or a Carotid Body Tumor Masquerading As a Lymph Node?

Vahid Roshanravan1, Ehsan Soltani2, Ehsan Hasanzadeh Haddad2, Ramin Sadeghi1, Azadeh Sahebkari1, Mahdi Mottaghi3, Atena Aghaee1.   

Abstract

A 53-year-old woman with a plantar malignant melanoma lesion was referred to our tertiary clinic for sentinel lymph node mapping. Lymphoscintigraphy with 99mTc-Phytate detected ipsilateral inguinal and popliteal sentinel nodes. After total resection of nodes, the pathology report confirmed that all specimens were involved by the tumor. As part of an institutional study evaluating somatostatin receptor avidity of melanoma by 99mTc-HYNIC-TOC scan, she also underwent a whole-body octreotide scan, which surprisingly showed intense tracer uptake in the right cervical region, confining in SPECT/CT images to a mass at the C2 spinal level, adjacent to the right carotid bifurcation. Neck surgery with gamma probe after injection of another dose of 99mTc-HYNIC-TOC was performed successfully, and the pathology report was consistent with a carotid body tumor. To best our knowledge, our case is the first one in the literature, which reports an incidental paraganglioma with 99mTc-HYNIC-TOC scan which resected via radio-guided surgery, again with 99mTc-HYNIC-TOC tracer.
© 2022 mums.ac.ir All rights reserved.

Entities:  

Keywords:  99mTc-HYNIC-TOC; 99mTc-Phytate; Carotid body tumor; Melanoma; Paraganglioma

Year:  2022        PMID: 35800421      PMCID: PMC9205846          DOI: 10.22038/AOJNMB.2021.59706.1415

Source DB:  PubMed          Journal:  Asia Ocean J Nucl Med Biol        ISSN: 2322-5718


Introduction

Paragangliomas are rare, slow-growing, and usually benign extra-adrenal neuroendocrine neoplasms of chromaffin-cell origin. Para-ganglionic tissues in the carotid body region are called carotid paraganglioma (also known as chemodectoma or carotid body tumor) (1). They can arise from different areas and are named accordingly, such as glomus tympani-cum, glomus jugulare, vagal paraganglioma, pulmonary paraganglioma, etc. (1). About 15-35 % of symptomatic cases could be metastatic (2). MRI is the standard imaging modality, but whole-body imaging by 99mTc-HYNIC-TOC is preferred for patients with risk factors for metastasis (i.e., larger tumors, high mitosis on pathologic study) (3). Best results are acquired using the Ga-68 DOTA-SSA; however, considering its low availability and high cost, a 99mTc-HYNIC-TOC scan would be an appropriate alternative (4). We present a case of incidental paraganglioma in a patient with melanoma who underwent an experimental 99mTc-HYNIC-TOC scan.

Case Report

A 53-year-old woman with a left plantar malignant melanoma lesion was referred to our department for sentinel lymph node mapping. Lymphoscintigraphy with 99mTc-Phytate detected sentinel lymph nodes in popliteal and inguinal regions. After resection of all nodes, a pathologic study confirmed the tumoral involvement of all nodes (Figure 1).
Figure1

a. The primary lesion was located in the surface of the right foot. b. Lymphoscintigraphy images shows sentinel nodes in popliteal and inguinal regions

a. The primary lesion was located in the surface of the right foot. b. Lymphoscintigraphy images shows sentinel nodes in popliteal and inguinal regions Then, we performed a 99mTc-HYNIC-TOC scan to evaluate the tumoral somatostatin receptor avidity as a part of an approved institutional study (IR.MUMS.MEDICAL.REC. 1400.032). Anterior and posterior whole-body images were obtained with GE healthcare Discovery NM/CT 670 DR dual-headed gamma cameras. The protocol included a 30 to 40minute acquisition (10 cm/min bed reposition) on a 1024×256 matrix with the Low Energy-High Resolution collimators and application of 140 keV peaks with a 15% window, four hours after tracer injection. Whole-body views revealed physiologic biodistribution of radiotracer throughout the body and a focus of intense tracer accumulation in the right side of the neck. Further localization showed a mass in the C2 level on the SPECT/CT images. The lesion was located close to the right common artery bifurcation (Figure2).
Figure2

Whole body Tc99m-HYNIC- toc scan shows intense uptake in the right cervical region

Whole body Tc99m-HYNIC- toc scan shows intense uptake in the right cervical region SPECT/CT scan from the neck four hours after tracer injection revealed a 1.5 cm round hypodense lesion with soft tissue density. It was located adjacent to the right common carotid artery bifurcation and showed intense 99mTc-HYNIC -TOC accumulation. These findings raised suspicion for a metastatic lymph node or a synchronous octreotide-avid neck tumor like a paraganglioma. The SPECT acquisition protocol includes a 30-minute stop and shot acquisition on a 64×64 matrix with the same collimators and peaks as mentioned previously. A Butterworth filter with that an order of 7.0 and a cutoff of 0.30 with attenuation and scatter correction were also used. A low dose CT scan was also performed simultaneously for attenuation correction and better localization of the mentioned lesion (Figure 3).
Figure3

SPECT/CT images localized the Octero avid lesion to a mass in the right cervical level II

SPECT/CT images localized the Octero avid lesion to a mass in the right cervical level II Since lymphatic metastasis to the neck is considered distant metastasis in plantar melanoma, the inguinal and popliteal complete dissections were postponed, and we decided to examine neck mass pathology first. The patient received 10 mCi of intravenous 99mTc-HYNIC-TOC, two hours before the surgery. During the surgery, we used a gamma probe to precisely localize and remove the mass (Figure 4). Pathological studies confirmed the diagnosis of a carotid body tumor. The patient underwent a complete dissection of inguinal and popliteal nodes in the same week and was referred to the oncology clinic for follow-up.
Figure4

The mentioned octero avid mass was successfully found with gamma probe during surgery

The mentioned octero avid mass was successfully found with gamma probe during surgery

Discussion

We present an incidental paraganglioma in a patient suffering from melanoma who underwent an experimental 99mTc-HYNIC -TOC scan. The importance of finding simultaneous melanoma and paraganglioma in a relatively middle- aged person raises suspicion for syndromic diseases; Wadt et al. proposed that mutations in BRCA1-associated protein-1 may make the patient susceptible to melanoma, para-ganglioma, and breast cancer. Diagnosis of these patterns, which are usually familial, is vital for future follow-ups of such patients (5). Additionally, even if we consider these situations sporadic, the accurate initial staging of melanoma is crucial to determine the prognosis and management (6). Multiple studies postulated different mechanisms for Peptide-targeted radionuclide therapy (7-10). Peptide-targeted therapeutic radionuclides, including 177Lu-DOTA-TATE, are developing methods that are used widely in the treatment of some somatostatin-expressing tumors, namely metastatic neuroendocrine tumors. Still, it warrants further investigation to be applied for metastatic octreotide-avid melanomas. In conclusion, our case is the first to describe an incidental finding of a paraganglioma by 99mTc-HYNIC-TOC scan, which was also resected via radio-guided surgery after injection of this tracer. The 99mTc-HYNIC-TOC scan could be a promising agent for detecting such lesions and associated metastases and radio-guided strategies to decrease surgical interventions and related morbidities.
  10 in total

1.  Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.

Authors:  Segolene Hescot; Maria Curras-Freixes; Timo Deutschbein; Anouk van Berkel; Delphine Vezzosi; Laurence Amar; Christelle de la Fouchardière; Nuria Valdes; Fernando Riccardi; Christine Do Cao; Jerome Bertherat; Bernard Goichot; Felix Beuschlein; Delphine Drui; Letizia Canu; Patricia Niccoli; Sandrine Laboureau; Antoine Tabarin; Sophie Leboulleux; Bruna Calsina; Rossella Libé; Antongiulio Faggiano; Martin Schlumberger; Francoise Borson-Chazot; Massimo Mannelli; Anne-Paule Gimenez-Roqueplo; Philippe Caron; Henri J L M Timmers; Martin Fassnacht; Mercedes Robledo; Isabelle Borget; Eric Baudin
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

2.  Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles.

Authors:  Xiuli Zhang; Feng Chen; Melik Z Turker; Kai Ma; Pat Zanzonico; Fabio Gallazzi; Manankumar A Shah; Austin R Prater; Ulrich Wiesner; Michelle S Bradbury; Michael R McDevitt; Thomas P Quinn
Journal:  Biomaterials       Date:  2020-02-19       Impact factor: 12.479

Review 3.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

Review 4.  Peptide-targeted radionuclide therapy for melanoma.

Authors:  Yubin Miao; Thomas P Quinn
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-02       Impact factor: 6.312

5.  Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide.

Authors:  Haixun Guo; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2013-02-24       Impact factor: 2.823

6.  A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.

Authors:  Karin Wadt; Jiyeon Choi; Joon-Yong Chung; Jens Kiilgaard; Steffen Heegaard; Krzysztof T Drzewiecki; Jeffrey M Trent; Stephen M Hewitt; Nicholas K Hayward; Anne-Marie Gerdes; Kevin M Brown
Journal:  Pigment Cell Melanoma Res       Date:  2012-10-01       Impact factor: 4.693

7.  EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Henri J Timmers; Elif Hindié; Benjamin A Guillet; Hartmut P Neumann; Martin K Walz; Giuseppe Opocher; Wouter W de Herder; Carsten C Boedeker; Ronald R de Krijger; Arturo Chiti; Adil Al-Nahhas; Karel Pacak; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

Review 8.  Paragangliomas of the head and neck.

Authors:  Phillip K Pellitteri; Alessandra Rinaldo; David Myssiorek; C Gary Jackson; Patrick J Bradley; Kenneth O Devaney; Ashok R Shaha; James L Netterville; Johannes J Manni; Alfio Ferlito
Journal:  Oral Oncol       Date:  2004-07       Impact factor: 5.337

9.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium.

Authors:  Kevin J H Allen; Rubin Jiao; Mackenzie E Malo; Connor Frank; Darrell R Fisher; David Rickles; Ekaterina Dadachova
Journal:  Pharmaceutics       Date:  2019-07-18       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.